De Jong WH - Search Results

1

Drug delivery and nanoparticles:applications and hazards.

De Jong WH, Borm PJ. De Jong WH, et al. Int J Nanomedicine. 2008;3(2):133-49. doi: 10.2147/ijn.s596. Int J Nanomedicine. 2008. PMID: 18686775 Free PMC article. Review.

2

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.

Giannakou C, Park MV, de Jong WH, van Loveren H, Vandebriel RJ, Geertsma RE. Giannakou C, et al. Among authors: de jong wh. Int J Nanomedicine. 2016 Jun 22;11:2935-52. doi: 10.2147/IJN.S102385. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27382281 Free PMC article. Review.

3

Nanomedicinal products: a survey on specific toxicity and side effects.

Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, Vandebriel RJ, Bosselaers IE, Scholl JH, Geertsma RE. Brand W, et al. Among authors: de jong wh. Int J Nanomedicine. 2017 Aug 22;12:6107-6129. doi: 10.2147/IJN.S139687. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28883724 Free PMC article.

4

What do we (need to) know about the kinetic properties of nanoparticles in the body?

Hagens WI, Oomen AG, de Jong WH, Cassee FR, Sips AJ. Hagens WI, et al. Among authors: de jong wh. Regul Toxicol Pharmacol. 2007 Dec;49(3):217-29. doi: 10.1016/j.yrtph.2007.07.006. Epub 2007 Aug 15. Regul Toxicol Pharmacol. 2007. PMID: 17868963 Review.

5

Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.

De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. De Jong WH, et al. Biomaterials. 2008 Apr;29(12):1912-9. doi: 10.1016/j.biomaterials.2007.12.037. Epub 2008 Feb 1. Biomaterials. 2008. PMID: 18242692

6

In vitro developmental toxicity test detects inhibition of stem cell differentiation by silica nanoparticles.

Park MV, Annema W, Salvati A, Lesniak A, Elsaesser A, Barnes C, McKerr G, Howard CV, Lynch I, Dawson KA, Piersma AH, de Jong WH. Park MV, et al. Among authors: de jong wh. Toxicol Appl Pharmacol. 2009 Oct 1;240(1):108-16. doi: 10.1016/j.taap.2009.07.019. Epub 2009 Jul 23. Toxicol Appl Pharmacol. 2009. PMID: 19631676

7

The status of in vitro toxicity studies in the risk assessment of nanomaterials.

Park MV, Lankveld DP, van Loveren H, de Jong WH. Park MV, et al. Among authors: de jong wh. Nanomedicine (Lond). 2009 Aug;4(6):669-85. doi: 10.2217/nnm.09.40. Nanomedicine (Lond). 2009. PMID: 19663595

8

The kinetics of the tissue distribution of silver nanoparticles of different sizes.

Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, Van Eijkeren JC, Geertsma RE, De Jong WH. Lankveld DP, et al. Among authors: de jong wh. Biomaterials. 2010 Nov;31(32):8350-61. doi: 10.1016/j.biomaterials.2010.07.045. Epub 2010 Aug 4. Biomaterials. 2010. PMID: 20684985

9

Genotoxicity evaluation of amorphous silica nanoparticles of different sizes using the micronucleus and the plasmid lacZ gene mutation assay.

Park MV, Verharen HW, Zwart E, Hernandez LG, van Benthem J, Elsaesser A, Barnes C, McKerr G, Howard CV, Salvati A, Lynch I, Dawson KA, de Jong WH. Park MV, et al. Among authors: de jong wh. Nanotoxicology. 2011 Jun;5(2):168-81. doi: 10.3109/17435390.2010.506016. Epub 2010 Aug 24. Nanotoxicology. 2011. PMID: 20735203

10

Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats.

Lankveld DP, Rayavarapu RG, Krystek P, Oomen AG, Verharen HW, van Leeuwen TG, De Jong WH, Manohar S. Lankveld DP, et al. Among authors: de jong wh. Nanomedicine (Lond). 2011 Feb;6(2):339-49. doi: 10.2217/nnm.10.122. Nanomedicine (Lond). 2011. PMID: 21385136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page